Status:
COMPLETED
Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment
Lead Sponsor:
Alnylam Pharmaceuticals
Conditions:
Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study provides a mechanism for continued administration of ALN-VSP02 therapy to patients with cancer who completed participation in another ALN-VSP02 clinical study. The primary objective of this...
Detailed Description
Study ALN-VSP02 is an extension study for previously conducted ALN-VSP02 studies. The study is being conducted to allow for continued ALN-VSP02 therapy for patients who completed participation in an A...
Eligibility Criteria
Inclusion
- Patient has completed a previous ALN-VSP02 study, and is deemed to have stable disease or better.
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
- Patient has adequate hematologic, liver, and renal function.
Exclusion
- Patient is receiving full-dose (therapeutic) anticoagulation therapy and/or aspirin \> 325 mg/day or other platelet inhibitory agents.
- Patient has clinically significant cardiovascular disease or uncontrolled serious cardiac arrhythmia.
- Patient has clinically significant cerebrovascular disease.
- Patient has a seizure disorder not controlled on medication.
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT01158079
Start Date
July 1 2010
End Date
September 1 2012
Last Update
October 12 2012
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
TGen Clinical Research Service at Scottsdale Healthcare
Scottsdale, Arizona, United States, 85258
2
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
3
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
4
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215